It's great to revisit all of the old Lalezari material again - some of the most sane material out there. But I'm not surprised to see the SP take a dump as only people who have followed Cytodyn and Leronlimab know the significance of Lalezari's move to CEO of Cytodyn.

There are a lot of weak hands out there who have been looking for a pop, even a small pop, to unload significant quantities of Cytodyn stock that they probably got cheaply. Or, in some cases, not so cheaply.

It's their mistake. Let those shares fall into our stronger, more faithful hands.

Good to see us going harder in the HIV direction. Although a lot of money thrown in that direction didn't get us much results, it wasn't all wasted and there are still some things to work with. And it seems we won't meet as much resistance from the FDA going in that direction.

Any forward progress will facilitate further progress. Let's stay narrowly focused for a while, even tho we know how promising Leronlimab is in so many indications. Let's follow a disciplined path for a while.